September 27, 2024 03:11 PM EDT
Pharma
FDA+
Law

US gov­ern­ment re­news threats over J&J's pro­posed 340B re­bate mod­el

Nicole DeFeudis

Editor

The fed­er­al gov­ern­ment re­newed its threats to John­son & John­son on Fri­day over the com­pa­ny’s pro­pos­al to change how some hos­pi­tals re­ceive drug price dis­counts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times